EA201791110A1 - Сублингвальное введение рилузола - Google Patents

Сублингвальное введение рилузола

Info

Publication number
EA201791110A1
EA201791110A1 EA201791110A EA201791110A EA201791110A1 EA 201791110 A1 EA201791110 A1 EA 201791110A1 EA 201791110 A EA201791110 A EA 201791110A EA 201791110 A EA201791110 A EA 201791110A EA 201791110 A1 EA201791110 A1 EA 201791110A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sublingual
rhynesol
riluzole
disclosed
introduction
Prior art date
Application number
EA201791110A
Other languages
English (en)
Inventor
Владимир Корик
Роберт М. Берман
Original Assignee
Биохэвен Фармасьютикэл Холдинг Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэвен Фармасьютикэл Холдинг Компани Лтд. filed Critical Биохэвен Фармасьютикэл Холдинг Компани Лтд.
Publication of EA201791110A1 publication Critical patent/EA201791110A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Раскрыто сублингвальное введение рилузола. В частности, настоящее изобретение относится к способу лечения психоневрологического расстройства или симптома с помощью введения сублингвального состава рилузола. Кроме того, раскрыт способ облегчения или уменьшения боли в ротовой полости с помощью сублингвального состава рилузола.
EA201791110A 2014-11-21 2015-11-17 Сублингвальное введение рилузола EA201791110A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (1)

Publication Number Publication Date
EA201791110A1 true EA201791110A1 (ru) 2017-11-30

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791110A EA201791110A1 (ru) 2014-11-21 2015-11-17 Сублингвальное введение рилузола

Country Status (14)

Country Link
US (1) US20180153862A1 (ru)
EP (1) EP3220890A1 (ru)
JP (1) JP2017535612A (ru)
KR (1) KR20170137030A (ru)
CN (1) CN107735077A (ru)
AU (1) AU2015350142A1 (ru)
BR (1) BR112017010440A2 (ru)
CA (1) CA2967659A1 (ru)
EA (1) EA201791110A1 (ru)
IL (1) IL252283A0 (ru)
MX (1) MX2017006454A (ru)
PH (1) PH12017500933A1 (ru)
SG (1) SG11201703897SA (ru)
WO (1) WO2016081466A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
SG11201703896QA (en) 2014-11-21 2017-06-29 Biohaven Pharm Holding Co Ltd Sublingual formulation of riluzole
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US11331303B2 (en) * 2016-09-15 2022-05-17 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
CA3090807A1 (en) 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US10235998B1 (en) 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
US20210059977A1 (en) * 2018-04-09 2021-03-04 The General Hospital Corporation Combination therapies for the treatment of amyotrophic lateral sclerosis and related disorders
KR20210024475A (ko) * 2018-05-27 2021-03-05 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
EA202190544A1 (ru) * 2018-08-16 2021-06-18 Биохэйвен Терапьютикс Лтд. Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
NZ515685A (en) * 1999-06-04 2002-12-20 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
JP6145946B2 (ja) * 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
CA3075331A1 (en) * 2012-03-01 2013-09-06 Pharnext New compositions for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
KR20170137030A (ko) 2017-12-12
JP2017535612A (ja) 2017-11-30
CN107735077A (zh) 2018-02-23
IL252283A0 (en) 2017-07-31
EP3220890A1 (en) 2017-09-27
BR112017010440A2 (pt) 2017-12-26
PH12017500933A1 (en) 2017-11-20
WO2016081466A1 (en) 2016-05-26
MX2017006454A (es) 2018-03-23
SG11201703897SA (en) 2017-06-29
AU2015350142A1 (en) 2017-06-15
CA2967659A1 (en) 2016-05-26
US20180153862A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
EA201791110A1 (ru) Сублингвальное введение рилузола
EA201790958A1 (ru) Сублингвальный препарат рилузола
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MY197698A (en) Oxysterols and methods of use thereof
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201491581A1 (ru) Везикулярные композиции
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MX2018011379A (es) Tratamiento del prurito uremico.
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
IN2013MU03428A (ru)
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
IN2014CH01391A (ru)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу